A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

NCT03416244 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Oesophageal Cancer
Oesophageal Cancer Metastatic
Esophageal Cancer Metastatic
Esophageal Cancers NOS
Oesophageal Cancer Nos
GastroEsophageal Cancer
Gastrooesophageal Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]